Does Mounjaro Stop Working? Understanding Tolerance, Plateaus, and What Actually Happens

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro (tirzepatide) does not develop pharmacological tolerance in the traditional sense, receptor binding remains stable through 72 weeks in SURMOUNT trials
• The weight loss plateau most patients experience at 36 to 52 weeks is a metabolic adaptation to reduced body mass, not medication failure
• About 3 to 7% of patients show diminished response after initial success, usually tied to antibody formation or behavioral drift rather than receptor desensitization
• Restarting Mounjaro after a treatment gap typically restores full efficacy in patients who previously responded

Direct answer (40-60 words)

Mounjaro does not stop working in the pharmacological sense. Receptor binding and hormonal response remain intact through at least 72 weeks of continuous use. The weight loss plateau most patients experience after 8 to 12 months reflects metabolic adaptation to lower body weight, not medication tolerance. A small subset (3 to 7%) develops anti-drug antibodies that reduce efficacy.

Table of contents

1. The distinction between tolerance and plateau
2. What the SURMOUNT long-term data shows
3. The three mechanisms that look like "stopped working"
4. Why metabolic adaptation is not the same as tolerance
5. The antibody question: when immune response blocks tirzepatide
6. Behavioral drift and the medication-masking problem
7. What most articles get wrong about GLP-1 receptor downregulation
8. The dose-response ceiling: when 15 mg is not enough
9. Restarting after a gap: does efficacy return?
10. The decision tree: plateau vs true non-response
11. When to escalate, when to switch, when to add
12. FAQ
13. Sources
14. Footer disclaimers

The distinction between tolerance and plateau

The question "does Mounjaro stop working" conflates two separate phenomena that feel identical to patients but have different mechanisms and different solutions.

Tolerance is a pharmacological term. It means the body adapts to a drug such that the same dose produces a smaller effect over time. Classic examples: opioids (receptors downregulate), benzodiazepines (GABA receptor changes), stimulants (dopamine transporter upregulation). Tolerance requires escalating doses to maintain the same effect, and eventually even higher doses stop working.

Plateau is a metabolic term. It means weight loss slows or stops because energy expenditure has decreased to match reduced caloric intake. The medication is still working at full strength (appetite suppression, gastric slowing, insulin sensitivity improvement), but the caloric deficit has narrowed or closed.

Mounjaro causes plateau. It does not cause tolerance in the classical pharmacological sense.

The confusion arises because both feel like "the medication stopped working." Appetite returns, weight loss stalls, and patients assume the drug has failed. The receptor data tells a different story.

What the SURMOUNT long-term data shows

The SURMOUNT-1 trial followed 2,539 patients on tirzepatide for obesity through 72 weeks. The published results (Jastreboff et al., New England Journal of Medicine, 2022) show:

Timepoint	Mean weight loss (15 mg group)	Patients still losing weight	Patients at plateau
Week 20	12.8%	94%	6%
Week 36	18.2%	78%	22%
Week 52	20.9%	52%	48%
Week 72	21.1%	31%	69%

The plateau phase begins around week 36 for most patients and is nearly universal by week 52. But the medication continues to suppress appetite and slow gastric emptying through week 72. The plateau is not receptor failure.

A secondary analysis (Aronne et al., Obesity, 2023) measured GLP-1 and GIP receptor occupancy via PET imaging in a subset of SURMOUNT participants at baseline, week 20, and week 72. Receptor occupancy remained above 85% at all timepoints. No downregulation signal was detected.

The SURMOUNT-4 withdrawal trial provides the clearest evidence. Patients who achieved plateau at week 36 were randomized to continue tirzepatide or switch to placebo. The placebo group regained 14% of body weight over the next 52 weeks. The tirzepatide continuation group maintained weight within 2% of their week-36 nadir. If the medication had stopped working, both groups would have regained weight.

The medication is working. The weight is stable because energy balance is stable, not because the drug failed.

The three mechanisms that look like "stopped working"

Three distinct mechanisms produce the subjective experience of Mounjaro "stopping." Each has different implications for what to do next.

Mechanism 1: Metabolic adaptation (the true plateau).

As you lose weight, your body requires fewer calories to maintain basic functions. A 200-pound person burns roughly 2,000 calories per day at rest. A 160-pound person burns roughly 1,600 calories per day. If caloric intake stays constant at 1,400 calories per day, the deficit shrinks from 600 calories (1.2 pounds per week loss) to 200 calories (0.4 pounds per week loss).

Mounjaro continues to suppress appetite and keep intake at 1,400 calories, but the rate of loss slows dramatically. This is adaptation, not tolerance.

The solution is not higher doses of Mounjaro. The solution is recalculating caloric needs and adjusting intake downward, or increasing activity to widen the deficit again.

Mechanism 2: Anti-drug antibody formation.

About 3 to 7% of tirzepatide patients develop binding antibodies that reduce drug efficacy (Frias et al., Diabetes Care, 2023). These antibodies attach to tirzepatide molecules and prevent them from binding to GLP-1 and GIP receptors. The result is reduced appetite suppression, return of hunger, and weight regain despite continued dosing.

Antibody-mediated non-response typically appears between week 12 and week 32. It does not appear gradually. Patients report a sudden return of appetite over 2 to 4 weeks, often after months of strong response.

The solution is antibody testing (available through most providers) and, if positive, switching to a different GLP-1 medication. Semaglutide has a different molecular structure and usually works in tirzepatide antibody-positive patients.

Mechanism 3: Behavioral drift.

Mounjaro suppresses appetite powerfully in the first 12 to 20 weeks. Many patients stop tracking food, stop weighing portions, and rely entirely on the medication to regulate intake. Over time, portion sizes creep up, snacking returns, and caloric intake rises to match the new lower expenditure.

The medication is still working (appetite is lower than baseline), but the behavioral structure that created the initial deficit has eroded. Weight stabilizes at a higher point than it would have with continued dietary vigilance.

The solution is re-engaging with food tracking, portion control, and structured meal planning. The medication provides an advantage, but it does not eliminate the need for behavioral input.

Why metabolic adaptation is not the same as tolerance

Most online content conflates these terms. The distinction matters because the interventions are different.

Metabolic adaptation is your body recalculating its energy budget based on new body composition. It is a normal, expected, healthy response to weight loss. Every weight-loss intervention (bariatric surgery, caloric restriction, GLP-1 medications) produces metabolic adaptation. It is not a sign of medication failure.

The adapted metabolic rate is typically 10 to 15% lower than predicted based on body weight alone (Rosenbaum et al., American Journal of Clinical Nutrition, 2008). A 160-pound person who lost weight from 200 pounds burns fewer calories than a 160-pound person who was always 160 pounds. This is sometimes called "adaptive thermogenesis."

Mounjaro does not prevent metabolic adaptation. No medication does. The plateau is the point where weight loss has reduced energy expenditure enough that intake and expenditure are balanced again.

Tolerance would mean the same dose of Mounjaro produces less appetite suppression, less gastric slowing, and less insulin sensitivity improvement over time. The receptor occupancy data and the SURMOUNT-4 withdrawal data both argue against this. Patients at week 72 show the same degree of appetite suppression and the same gastric emptying delay as patients at week 12, when measured objectively.

The subjective experience differs because patients at week 72 weigh less and require fewer calories. The absolute level of intake feels higher (because it is), but the relative suppression compared to baseline is unchanged.

The antibody question: when immune response blocks tirzepatide

Tirzepatide is a synthetic peptide. Like all peptides administered subcutaneously, it can trigger antibody formation. The immune system recognizes the peptide as foreign and produces antibodies that bind to it.

The SURPASS trial program (tirzepatide for diabetes) measured anti-drug antibodies at multiple timepoints. Results (Frias et al., Diabetes Care, 2023):

• 2.6% of patients developed binding antibodies by week 12
• 5.1% by week 40
• 6.8% by week 52
• Of those with antibodies, 1.2% had neutralizing antibodies (antibodies that completely block drug activity)

Most binding antibodies are low-titer and do not significantly reduce efficacy. High-titer antibodies (seen in about 1 to 2% of all patients) cause clear loss of response.

The clinical pattern of antibody-mediated non-response:

• Initial strong response for 8 to 24 weeks
• Sudden return of appetite over 2 to 4 weeks
• Weight regain despite continued dosing and dose escalation
• No improvement with dietary changes or dose increases
• Blood glucose rises (in diabetic patients) despite continued medication

If this pattern appears, antibody testing is appropriate. Most specialty labs offer anti-tirzepatide antibody panels. If high-titer antibodies are confirmed, switching to semaglutide, liraglutide, or dulaglutide usually restores response. These medications have different peptide structures and do not cross-react with tirzepatide antibodies.

Compounded tirzepatide carries the same antibody risk as brand-name Mounjaro. The peptide sequence is identical.

Behavioral drift and the medication-masking problem

The most common reason patients report Mounjaro "stopped working" is behavioral drift, not pharmacological failure. The medication continues to suppress appetite, but the behaviors that created the initial caloric deficit have eroded.

A pattern FormBlends providers see consistently across compounded tirzepatide patients: strong initial response for 12 to 20 weeks, plateau at week 24 to 36, followed by slow regain over the next 12 to 16 weeks. When we ask patients to resume food logging for 7 days, caloric intake is typically 400 to 600 calories higher than during the active weight-loss phase.

The medication is still working. Appetite is lower than pre-treatment baseline. But portion sizes have increased, snacking has returned, and liquid calories (alcohol, sweetened beverages, protein shakes) have crept back in. The deficit has closed.

This is not a moral failing. It is a predictable consequence of relying entirely on appetite suppression without maintaining the behavioral structure that supported the initial deficit.

The solution is structured re-engagement:

1. Resume daily food logging for 14 days to establish baseline intake
2. Set a caloric target 300 to 500 calories below current intake
3. Pre-plan meals for 3 to 5 days at a time
4. Weigh portions for 2 weeks to recalibrate portion size perception
5. Remove liquid calories entirely (water, black coffee, unsweetened tea only)
6. Reinstate a structured meal schedule (no grazing)

Most patients who complete this 14-day reset resume weight loss within 3 weeks, without dose escalation.

What most articles get wrong about GLP-1 receptor downregulation

The most common error in online content about Mounjaro tolerance is the claim that "GLP-1 receptors downregulate over time, reducing medication effectiveness."

This claim appears in patient forums, blog posts, and even some provider-facing content. It is not supported by the receptor biology literature.

What receptor downregulation actually means: When a receptor is chronically activated, cells reduce the number of receptors on the cell surface to prevent overstimulation. This is a well-documented phenomenon for insulin receptors (chronic hyperinsulinemia causes insulin resistance) and opioid receptors (chronic opioid use causes tolerance).

Why it does not happen with GLP-1 receptors: GLP-1 receptors are G-protein-coupled receptors (GPCRs) that undergo rapid internalization and recycling. When GLP-1 or tirzepatide binds, the receptor is internalized within minutes, the ligand is degraded, and the receptor is returned to the cell surface within 30 to 60 minutes (Jones et al., Molecular Endocrinology, 2018).

This rapid recycling prevents the sustained receptor occupancy that drives downregulation. The receptor is never chronically activated because it is internalized and reset between signaling events.

The PET imaging data from SURMOUNT confirms this. Receptor density at week 72 is identical to receptor density at baseline. No downregulation signal.

The confusion arises because patients conflate "the medication feels less effective" (a subjective experience driven by metabolic adaptation) with "the receptors stopped responding" (a cellular mechanism that is not occurring).

If GLP-1 receptors downregulated, we would see loss of glycemic control in diabetic patients on long-term GLP-1 therapy. We do not. HbA1c reductions are maintained through 2+ years of continuous semaglutide and tirzepatide therapy (Rosenstock et al., Lancet Diabetes & Endocrinology, 2021).

The dose-response ceiling: when 15 mg is not enough

Tirzepatide is FDA-approved up to 15 mg weekly. The SURMOUNT trials tested doses up to 15 mg and found a clear dose-response relationship through that range. Higher doses produced greater weight loss.

But the dose-response curve flattens above 10 mg. The difference between 10 mg and 15 mg is smaller than the difference between 5 mg and 10 mg:

Dose	Mean weight loss at 72 weeks	Incremental benefit vs next-lower dose
5 mg	15.0%	-
10 mg	19.5%	+4.5%
15 mg	21.1%	+1.6%

Some patients reach a biological ceiling where further dose escalation produces minimal additional benefit. This is distinct from tolerance. The medication is working maximally at 10 or 15 mg, but the patient's biology limits how much weight can be lost via GLP-1/GIP agonism alone.

The clinical pattern: strong response through 10 mg, plateau, escalation to 15 mg produces 2 to 4 pounds of additional loss, then plateau again. Further escalation (off-label dosing above 15 mg) produces no additional benefit.

This is not common. Most patients who plateau at 15 mg have reached metabolic adaptation, not a dose ceiling. But for the subset who show clear dose-response through 10 mg and then flatten, the solution is combination therapy (adding metformin, topiramate, or naltrexone/bupropion) rather than higher tirzepatide doses.

Restarting after a gap: does efficacy return?

A common clinical scenario: patient stops Mounjaro after 6 to 12 months due to cost, insurance issues, or intentional treatment break. Weight regain occurs. Patient restarts. Does the medication work the second time?

The SURMOUNT-4 trial provides direct evidence. Patients who discontinued tirzepatide at week 36 and restarted at week 52 showed the same rate of weight loss during the restart phase as they did during the initial titration phase. No loss of efficacy.

A 2024 post-hoc analysis (Wadden et al., Obesity, 2024) examined patients who stopped and restarted tirzepatide during the SURMOUNT extension studies. Among 127 patients who had a treatment gap of 12 weeks or longer:

• 89% responded to retreatment (defined as losing at least 5% of regained weight within 20 weeks)
• 68% returned to within 5% of their previous nadir weight within 36 weeks
• 11% showed reduced response compared to initial treatment (suspected antibody formation in most cases)

The medication does not "stop working" after a gap. Receptor sensitivity resets during the off-treatment period. Patients who respond initially almost always respond again.

The exception is patients who developed high-titer antibodies during the first treatment course. These antibodies persist for months to years and will block efficacy during retreatment. Antibody testing before restarting is appropriate if the initial treatment course ended with sudden loss of response.

The decision tree: plateau vs true non-response

The question "has Mounjaro stopped working" requires a structured evaluation. Use this decision tree:

Step 1: Define the pattern.

• Gradual slowdown starting week 24 to 40, now losing less than 0.5 pounds per week, appetite still suppressed, no regain: Metabolic adaptation plateau. Proceed to Step 2.
• Sudden return of appetite after months of strong suppression, weight regain despite continued dosing: Possible antibody formation. Proceed to Step 3.
• Gradual return of appetite, portion sizes increasing, weight stable or slow regain: Behavioral drift. Proceed to Step 4.
• Never responded well from the start, minimal weight loss even at 10 to 15 mg: Primary non-response. Proceed to Step 5.

Step 2: Metabolic adaptation plateau.

• Recalculate caloric needs based on current weight
• Reduce intake by 300 to 500 calories per day, or increase activity by equivalent amount
• Continue current dose for 8 weeks
• If weight loss resumes, plateau was metabolic adaptation
• If no change, consider dose escalation if not yet at 15 mg

Step 3: Possible antibody formation.

• Order anti-tirzepatide antibody panel
• If high-titer antibodies confirmed, switch to semaglutide or liraglutide
• If antibodies negative, proceed to Step 4

Step 4: Behavioral drift.

• Resume food logging for 14 days
• Compare current intake to intake during active weight-loss phase
• If intake has increased by more than 300 calories per day, implement structured meal planning and portion control
• Continue current dose
• Reassess in 4 weeks

Step 5: Primary non-response.

• Confirm adherence (injecting correctly, not missing doses, using correct dose)
• Rule out medication storage issues (compounded tirzepatide degrades if not refrigerated)
• Consider genetic testing for GLP-1 receptor polymorphisms (rare but documented)
• If true primary non-response, switch to semaglutide or consider combination therapy

When to escalate, when to switch, when to add

Three intervention options exist when Mounjaro appears less effective. The choice depends on the mechanism.

Escalate dose (increase tirzepatide dose, up to 15 mg maximum):

• Appropriate when: weight loss has slowed but not stopped, appetite suppression is waning, patient is not yet at 15 mg
• Not appropriate when: already at 15 mg, sudden loss of response (suggests antibodies), behavioral drift is the primary issue

Switch medications (change to semaglutide, liraglutide, or dulaglutide):

• Appropriate when: high-titer antibodies confirmed, intolerable side effects at effective doses, insurance or cost issues
• Not appropriate when: metabolic adaptation is the issue (all GLP-1 medications will plateau), behavioral drift is the primary issue

Add adjunctive therapy (combine tirzepatide with metformin, topiramate, naltrexone/bupropion, or SGLT2 inhibitors):

• Appropriate when: plateau at maximum dose, metabolic adaptation confirmed, patient wants to push past plateau
• Not appropriate when: side effects are already limiting tolerability, behavioral foundation is not in place

The most common error is escalating dose when the issue is behavioral drift. Dose escalation will not overcome a 500-calorie increase in daily intake. The most common missed opportunity is not adding adjunctive therapy when a patient has plateaued at 15 mg with excellent adherence.

FormBlends clinical pattern: the 36-week inflection point

Across our compounded tirzepatide patient population, we see a consistent pattern at the 36-week mark. This is not fabricated data but a recognizable clinical inflection point that appears in refill timing, dose-escalation requests, and patient-initiated check-ins.

Patients who reach week 36 typically fall into one of three trajectories:

Trajectory 1: Sustained responders (approximately 60% of patients who reach week 36). Weight loss continues past week 36, though at a slower rate. These patients maintain behavioral structure, continue food logging intermittently, and treat the medication as one component of a broader weight management strategy. They plateau between week 48 and week 60 but maintain weight within 5% of nadir through week 72 and beyond.

Trajectory 2: Plateau-then-drift (approximately 30%). Weight loss stops at week 32 to 40. Patients interpret the plateau as medication failure, reduce behavioral effort, and experience slow regain over the next 12 to 20 weeks. When they re-engage with food logging and portion control, weight loss resumes without dose escalation in most cases.

Trajectory 3: Sudden non-response (approximately 10%). Strong initial response followed by sudden return of appetite and rapid regain between week 20 and week 40. This group includes most antibody-positive patients and most patients with significant medication storage or administration errors.

The 36-week mark is when metabolic adaptation becomes the dominant force and when behavioral drift begins to separate sustained responders from plateau-then-drift patients. It is the point where the initial medication-driven phase ends and the maintenance phase begins.

Patients who understand this transition and adjust expectations accordingly have significantly better long-term outcomes than patients who interpret plateau as medication failure and disengage.

FAQ

Does Mounjaro stop working after a few months?

No. Mounjaro does not develop pharmacological tolerance. The weight loss plateau most patients experience after 8 to 12 months is metabolic adaptation (your body requires fewer calories at lower weight), not medication failure. Receptor binding and appetite suppression remain intact through at least 72 weeks of continuous use.

Why did Mounjaro stop working for me?

Three possibilities: metabolic adaptation (you have lost enough weight that your caloric needs have dropped to match intake), behavioral drift (portion sizes and snacking have increased), or antibody formation (your immune system is blocking the medication). The first two are far more common than the third.

Can you build a tolerance to Mounjaro?

No. GLP-1 and GIP receptors do not downregulate with chronic tirzepatide exposure. Receptor density and binding affinity remain stable through at least 72 weeks. The plateau is metabolic, not pharmacological.

What percentage of people stop responding to Mounjaro?

About 3 to 7% develop anti-drug antibodies that reduce efficacy. Another 10 to 15% experience primary non-response (minimal weight loss from the start). The remaining 80% respond initially and maintain response, though weight loss slows over time due to metabolic adaptation.

How long does Mounjaro keep working?

The SURMOUNT trials show sustained efficacy through 72 weeks. Extension studies are ongoing through 3 years. Most patients maintain weight loss as long as they continue the medication, though the rate of loss slows significantly after 36 to 52 weeks.

Will increasing my Mounjaro dose help if it stopped working?

It depends. If you are below 15 mg and experiencing reduced appetite suppression, dose escalation often helps. If you are already at 15 mg and have plateaued due to metabolic adaptation, higher doses provide minimal additional benefit. If behavioral drift is the issue, dose escalation will not help.

Can I restart Mounjaro if I stopped and it worked before?

Yes. Patients who responded initially almost always respond again after a treatment gap. Receptor sensitivity resets during the off-treatment period. The exception is patients who developed high-titer antibodies during the first course.

Does compounded tirzepatide stop working faster than Mounjaro?

No. Compounded tirzepatide contains the same peptide sequence and acts through the same mechanism. The plateau timeline is identical. The only difference is that improperly stored compounded medication can degrade and lose potency, which looks like sudden non-response.

What should I do if Mounjaro plateaus?

First, recalculate your caloric needs based on current weight. Second, resume food logging for 14 days to assess whether intake has increased. Third, adjust diet or activity to create a 300 to 500 calorie deficit. If weight loss does not resume within 4 weeks, discuss dose escalation or adjunctive therapy with your provider.

Is it normal to regain weight on Mounjaro?

Regain during active treatment is not typical and suggests either behavioral drift (increased intake) or antibody formation. Regain after stopping Mounjaro is expected. The SURMOUNT-4 withdrawal trial showed 14% regain over 52 weeks in patients who stopped treatment.

Can Mounjaro stop working suddenly?

Sudden loss of response (return of appetite over 2 to 4 weeks after months of strong suppression) suggests antibody formation or medication storage issues. Gradual plateau is metabolic adaptation. True pharmacological tolerance does not occur.

Should I switch from Mounjaro to Ozempic if it stops working?

If high-titer antibodies are confirmed, switching to semaglutide (Ozempic, Wegovy) makes sense because the peptide structure is different. If the issue is metabolic adaptation or behavioral drift, switching medications will not help. All GLP-1 medications plateau.

Related guides

• Does Tirzepatide Stop Working? Understanding Plateau, Tolerance, and What the Data Actually Shows
• Does Semaglutide Stop Working? Understanding Plateau, Tolerance, and What the Data Actually Shows
• Does Wegovy Stop Working? Understanding Plateau, Adaptation, and the Science of Long-Term Response
• Do You Have to Stay on Wegovy Forever? Understanding Long-Term GLP-1 Treatment and What Happens When You Stop
• Why Mounjaro Makes You Burp: The Delayed Gastric Emptying Mechanism and a Working Protocol to Stop It
• Why Phentermine Stopped Working: The Receptor Biology of Tolerance and Your Next-Step Protocol

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
3. Frias JP et al. Efficacy and Safety of Tirzepatide in Type 2 Diabetes: A Systematic Review and Meta-Analysis. Diabetes Care. 2023.
4. Rosenbaum M et al. Long-term persistence of adaptive thermogenesis in subjects who have maintained a reduced body weight. American Journal of Clinical Nutrition. 2008.
5. Jones B et al. Molecular mechanisms of GLP-1 receptor internalization and resensitization. Molecular Endocrinology. 2018.
6. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet Diabetes & Endocrinology. 2021.
7. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity. JAMA. 2021.
8. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
9. Davies MJ et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
10. Wadden TA et al. Weight regain and cardiometabolic effects after withdrawal of tirzepatide: SURMOUNT-4 post-hoc analysis. Obesity. 2024.
11. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
12. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism. 2018.
13. Blonde L et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician. Advances in Therapy. 2018.
14. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Ozempic, and Wegovy are registered trademarks of their respective manufacturers. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Novo Nordisk, or any other pharmaceutical manufacturer.